GlassScriptPhysician profile
Manpreet Kaur Multani
NPI 1679706295
$7,529.06
in general payments reported to CMS, 2019-2025
55 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $229 · 2021: $720 · 2022: $1,120 · 2023: $1,941 · 2024: $2,180 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,122 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,121.72 |
| Education | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $962.12 | 2019-2025 | |
| Abbvie INC. | $961.98 | 2021-2025 | |
| Csl Behring | $512.28 | 2020-2025 | Hizentra |
| Ucb, INC. | $480.78 | 2022-2025 | Briviact, Nayzilam |
| Alexion Pharmaceuticals, INC. | $422.86 | 2021-2025 | Ultomiris, Soliris |
| Biogen, INC. | $352.01 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Eisai INC. | $303.63 | 2021-2025 | |
| Banner Life Sciences, LLC | $280.57 | 2021-2022 | |
| Lilly USA, LLC | $260.98 | 2021-2024 | Amyvid, Kisunla, Emgality |
| Pfizer INC. | $256.34 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $193.01 | 2023-2025 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $187.52 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $173.74 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Argenx US, INC. | $172.10 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $138.06 | 2020-2024 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manpreet Multani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.